Contrast Media

Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.

Bracco's Syringeless MR Injector Receives FDA Approval
Nov. 25, 2025 —Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for the Bracco-branded Max 3, a Rapid Exchange and Syringeless Injector for use in magnetic resonance imaging (MRI) procedures.
New MRI Contrast Agent Design Helps Provide Safer, More Effective Diagnostics
Nov.
VIDEO: Talking Trends with Bayer Radiology — Navigating Market Disruptions to Your CT Suite
Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different challenges and market disruptions they are currently facing and some of the innovative solutions that Bayer can offer them to…
Bayer Receives FDA Clearance for CT Injection System
Nov. 7, 2024 — Bayer announced it has received 510(k) clearance from the U.S.
Market Analysis: Vendor Focus on Optimizing Patient Safety and Radiology Workflow Drives Growth
Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in tissues, allowing for improved visualization…

News | Contrast Media

FDA Expands Approval of Low-Dose MRI Contrast Agent to Include Neonates and Infants

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

February 24, 2026

News | FDA

Bracco's Syringeless MR Injector Receives FDA Approval

Nov. 25, 2025 —Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

November 26, 2025

News | Contrast Media

New MRI Contrast Agent Design Helps Provide Safer, More Effective Diagnostics

Nov. 10, 2025 — Scientists at the University of Birmingham have developed a new class of MRI contrast agents – improving ...

November 10, 2025

Sponsored Content

Videos | Radiology Business

VIDEO: Talking Trends with Bayer Radiology — Navigating Market Disruptions to

Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different ...

October 09, 2025

Study Shows Positive Results Investigating AI to Lower Gadolinium Dose in CE-MRI

News | Contrast Media

Study Shows Positive Results Using AI to Lower Gadolinium Dose in CE-MRI

Oct. 21, 2025 — Subtle Medical, Inc., a provider of AI-powered medical imaging solutions, has announced positive ...

October 21, 2025

Sponsored Content | Sponsored Content | Videos | Radiology Business

VIDEO: Talking Trends with Bayer Radiology — Navigating Market Disruptions to Your CT Suite

Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different ...

October 09, 2025

News | Contrast Media

Bayer Files for Approval of Investigational Contrast Agent in the U.S.

June 17, 2025 — Bayer has announced the submission of a New Drug Application (NDA) to the US Food and Drug ...

June 20, 2025

Sponsored Content

Videos | Contrast Media

VIDEO: Talking Trends with Bracco: Investing in the Future of Radiology

Bracco Diagnostics and Guerbet recently announced they had formed a strategic, global collaboration for the research ...

February 27, 2023

News | Ultrasound Imaging

Study: Contrast-Enhanced Ultrasound is Safe, Saves lives

May 14, 2025 — A comprehensive new study based on nationwide claims data from more than 11 million patients shows that ...

May 14, 2025

News | Contrast Media

Bracco, Zereau Launch Research Program to Improve Sustainability in Medical Imaging

Feb. 26, 2025 — Bracco Imaging SpA and Zereau BV, a provider of unique water technology for the healthcare sector, have ...

March 03, 2025

News | Contrast Media

Photon-Counting Detector CT, Gadoxetate Disodium Show Hepatic Enhancement on Phantom

Feb. 5, 2025 — According to research published in the American Journal of Roentgenology (AJR), photon-counting detector ...

February 07, 2025

Sponsored Content

Case Study | SPECT-CT

Making the Invisible Visible: Spectral CT 7500 Transforms Patient Care with

A patient’s chance of recovery can be directly impacted when a diagnosis is missed or delayed. To get the right ...

July 06, 2022

News | Contrast Media

Investigational MRI Contrast Agent Meets Primary and Main Secondary Endpoints in Phase III Studies

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

January 14, 2025

News | Contrast Media Injectors

Bayer Receives FDA Clearance for CT Injection System

Nov. 7, 2024 — Bayer announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

November 08, 2024

Bracco and Blue Earth Diagnostics has announced the appointment of Marco Campione as new CEO, effective immediately. Campione succeeds David Gauden, D. Phil., who now assumes the role of CEO of Bracco subsidiary Blue Earth Therapeutics.

News | Radiology Business

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

July 09, 2024

Sponsored Content

Lawrence N. Tanenbaum, MD FACR is Vice President/Chief Technology Officer Director of CT, MR, and Advanced Imaging for RadNet with 37+ years experience in the medical field. He is a member of editorial boards of several journals/educational organizations and reviewer for scientific journals. He has authored 100+ scholarly and peer-reviewed articles, chairs educational/academic meetings, and has delivered 2000+ invited global lectures.

Case Study | Contrast Media Injectors

Case Studies with Lawrence N. Tanenbaum, MD FACR Using Macrocyclic CLARISCAN

Product Indications and Use: CLARISCAN (gadoterate meglumine) is a gadolinium-based contrast agent indicated for ...

May 03, 2022

Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.

News | Contrast Media

Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

May 08, 2024

The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) today announced an educational partnership to help train sonographers to perform contrast-enhanced ultrasound (CEUS) examinations and administer intravenous ultrasound contrast agents

News | Contrast Media

International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums Announce Partnership to Advance IV Training for Sonographers

April 24, 2024 — The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) announced an ...

April 24, 2024

LUMISIGHT and Lumicell Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries

News | FDA

Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

April 18, 2024

Collaboration includes robust education and training to support radiologists and imaging specialists

News | Mammography

Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

April 12, 2024

The latest MyBreastAI Suite supports clinicians in accelerating breast cancer detection, while the company’s Pristina Bright solution helps healthcare providers start a new contrast program

News | Mammography

GE HealthCare to feature Mobile Mammography Screening Truck along with Latest AI Platform as part of SBI2024 Breast Cancer Imaging Showcase

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

April 12, 2024

Ga-68 has a very short half-life, which presents logistical challenges in distribution

News | Radiopharmaceuticals and Tracers

RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

April 05, 2024

During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.

News | Molecular Imaging

Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

March 29, 2024

News | Breast Imaging

Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT in the Detection of Cancerous Tissue During Breast Conserving Surgery

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

March 08, 2024